PDE4 targeted therapies have shown promising results in various neurological disorders such Alzheimer’s disease (AD), Parkinson’s disease (PD), Fragile X Syndrome, depression and neuropathic pain(17). This evidence concerns the gene PDE4A and early-onset autosomal dominant Alzheimer disease.